GOSS
Gossamer Bio, Inc.
There isn't enough reported data to score GOSS yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GOSS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
GOSS's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GOSS PE Valuation
GOSS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GOSS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GOSS's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GOSS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$46.56 | +$7.84 |
| Q2 2026 | -$56.00 | -$7.20 |
| Q1 2026 | -$63.20 | -$45.60 |
| Q4 2025 | -$60.00 | -$40.00 |
| Q3 2025 | -$54.40 | -$45.60 |
| Q2 2025 | -$48.80 | -$34.40 |
| Q1 2025 | -$17.60 | +$50.40 |
| Q4 2024 | -$20.00 | +$74.40 |
GOSS is still losing money, but far less than before: $46.56 per share over the past year, against $284.80 at its worst in mid-2020.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over GOSS on earnings, with more consistent year-over-year improvement.
GOSS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $38.4M | +189% |
| Q2 2026 | $9.2M | -20% |
| Q1 2026 | $17M | +71% |
| Q4 2025 | $13.8M | +47% |
| Q3 2025 | $13.3M | +40% |
| Q2 2025 | $11.5M | -88% |
GOSS's revenue is recovering but still below its 2024 peak: $38M last quarter, up 189% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +388 points |
| Q2 2026 | -282% | +55 points |
| Q1 2026 | -265% | +108 points |
| Q4 2025 | -334% | +52 points |
| Q3 2025 | -369% | -12 points |
| Q2 2025 | -337% | -392 points |
| Q1 2025 | -372% | N/A |
| Q4 2024 | -385% | N/A |
GOSS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GOSS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$29.6M | +$6.6M |
| Q2 2026 | -$39.4M | +$7.7M |
| Q1 2026 | -$38.7M | +$1M |
| Q3 2025 | -$36.2M | -$4.1M |
| Q2 2025 | -$47.1M | -140% |
| Q1 2025 | -$39.8M | +$12.6M |
| Q3 2024 | -$32M | +$2.5M |
| Q2 2024 | $116.3M | +$154.6M |
GOSS has burned cash in almost every quarter: −$156M over the past year, against −$155M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GOSS on cash generation, producing positive trailing cash flow while its opponent burns cash.
GOSS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +59% | +2.4M shares |
| 1 year | +129% | +3.7M shares |
| 3 years | +447% | +5.3M shares |
| 5 years | +600% | +5.6M shares |
| Available history | +854% | +5.8M shares |
GOSS has 7M diluted shares, up 129% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GOSS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GOSS Net Leverage
GOSS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GOSS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.1 | Neutral |
| Stochastic | 22.1 | Neutral |
GOSS's weekly RSI is 32 (neutral) and its Stochastic is 22 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GOSS PE vs Healthcare Sector
GOSS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GOSS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 11% above |
| 20 week MA | $11.7 | 4% below |
| 50 week MA | $67.1 | 83% below |
| 100 week MA | $100.3 | 89% below |
| 200 week MA | $92.8 | 88% below |
GOSS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GOSS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,247.2 | $801.6 | -36% |
| 2021 | $801.6 | $931.2 | +16% |
| 2022 | $931.2 | $152.0 | -84% |
| 2023 | $152.0 | $73.0 | -52% |
| 2024 | $73.0 | $68.4 | -6.3% |
| 2025 | $68.4 | $258.4 | +278% |
| 2026 YTD | $258.4 | $11.2 | -96% |
GOSS's yearly returns have swung widely, from +278% in 2025 to −84% in 2022. It's down 96% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over GOSS on returns for 2026, with the stronger performance.